Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
RECORDATI: RISULTATI ECONOMICI POSITIVI NEL PRIMO SEMESTRE DEL 2020. RICAVI +2,3%, EBITDA +11,4%, UTILE NETTO RETTIFICATO +16,8% Ricavi netti consolidati € 760,2 milioni, +2,3%.EBITDA (1) € 311,1...
-
RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET INCOME +16.8% Consolidated revenues € 760.2 million, +2.3%.EBITDA (1) € 311.1 million,...
-
RECORDATI: ISTURISA® (OSILODROSTAT) STUDIO DI FASE III LINC-4 RAGGIUNGE L’ENDPOINT PRIMARIO NELLA MALATTIA DI CUSHING Isturisa® (osilodrostat) dimostra un significativo e sostenuto beneficio contro...
-
RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE Isturisa® (osilodrostat) demonstrates significant and sustained benefit over placebo at...
-
RECORDATI: RISULTATI ECONOMICI IN CRESCITA NEL PRIMO TRIMESTRE DEL 2020. RICAVI +12,1%, EBITDA +20,1%. Ricavi netti consolidati € 429,2 milioni, +12,1%.EBITDA (1) € 172,9 milioni, +20,1%.Utile...
-
RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%. Consolidated revenues € 429.2 million, +12.1%.EBITDA (1) € 172.9 million, +20.1%Operating income € 148.4 million,...
-
RECORDATI: L’ASSEMBLEA APPROVA IL BILANCIO DEL 2019. DIVIDENDO DI € 1,00 PER OGNI AZIONE (+8,7% vs 2018). L’Assemblea approva il bilancio 2019: ricavi netti consolidati € 1.481.8 milioni (+9,6% vs...
-
RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018). Shareholders approve the 2019 results: consolidated revenues € 1,481.8 million (+9.6% vs 2018), EBITDA...
-
Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome Paris, 8 April, 2020 –...
-
RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN Milan, 26 March 2020 – Recordati announces the submission of the Japanese New Drug Application (JNDA) to the Ministry of Health, Labour...